The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Commentary|Videos|February 12, 2026
Exploring the Rationale Behind University of Chicago’s Bionic Breast Program
Author(s)Stacy Tessler Lindau, MD, MA
Fact checked by: Kyle Doherty
Stacy Tessler Lindau, MD, MA, discusses the background of the Bionic Breast program at University of Chicago.
Advertisement
Stacy Tessler Lindau, MD, MA, provides that rationale for initiating the Bionic Breast program at the University of Chicago. The goal of the program is to restore sensation and ultimately full breast functionality following mastectomy for patients with breast cancer. Lindau notes that many women who undergo mastectomy lose all sensation and often experience chronic pain in the breast area.
Advertisement
Related to this article
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.
Gabriela Hobbs, MD, explains the importance of risk assessment and using disease factors to drive management approaches in myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
3
Micvotabart Pelidotin Monotherapy Yields Responses in Pretreated Recurrent/Metastatic HNSCC
4
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
5